Company news

Myriad Genetics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022

July 27, 2022

Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022

July 18, 2022

Access to Myriad Genetics’ GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial

July 11, 2022

Myriad Genetics Issues Inaugural Environmental, Social and Governance Report

June 27, 2022

Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration

June 22, 2022

Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference

June 8, 2022

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

May 25, 2022

Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022

May 4, 2022

Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference

May 3, 2022

Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions

May 2, 2022

Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022

April 27, 2022

2 Out of 3 Women With Depression or Anxiety Say They’ve Reached Their “Breaking Point” Yet More than Half Wait a Year Before Seeking Treatment

April 25, 2022

Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care

March 13, 2022

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer

March 10, 2022

Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies

March 7, 2022

Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference

March 1, 2022

Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives

February 23, 2022

New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test

February 22, 2022

Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022

February 15, 2022

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

February 13, 2022

Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference

January 4, 2022

Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service

January 3, 2022

The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young Adults

December 14, 2021

New Year’s Resolutions: Americans Say Body & Mind Equally Important in Theory but Not in Practice, According to GeneSight® Mental Health Monitor Nationwide Survey

December 14, 2021

Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer

December 13, 2021

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and Treatment

November 21, 2021

Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans

November 1, 2021

Myriad Genetics to Release Third Quarter Financial Results on November 2, 2021

October 26, 2021

Myriad Genetics Names Pamela Wong as Chief Legal Officer

October 17, 2021

Myriad Genetics Completes Sale of Myriad Autoimmune’s Vectra Testing Business to LabCorp

September 12, 2021

Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans

August 2, 2021

Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries

August 1, 2021

Myriad Genetics to Release Second Quarter Financial Results on August 3, 2021

July 27, 2021

Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities

July 20, 2021

Myriad Genetics Completes Sale of Myriad RBM to IQVIA’s Q2 Solutions

June 30, 2021

Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics

June 15, 2021

Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

May 31, 2021

Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions

May 23, 2021

Myriad Genetics Appoints Melissa Gonzales to Lead Women’s Health Business

May 19, 2021

Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

May 18, 2021

Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp

May 2, 2021

Myriad Genetics to Release March 2021 Quarterly Financial Results on May 3, 2021, Host Investor Day on May 4, 2021

April 26, 2021

Myriad Genetics Announces Eric Santa as Chief Growth Officer, Names New Diversity and Marketing Leaders

March 28, 2021

Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services

March 1, 2021

Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan

February 22, 2021

Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021

February 15, 2021

Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis

February 1, 2021

Myriad Genetics Forms Strategic Partnership with Illumina in Oncology

January 10, 2021

Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations

January 4, 2021

Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China

November 15, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 48 decks. Every deck is listed under its year.